進階搜尋

 
查詢範圍:「   」
顯示範圍:第筆 論文書目資料
顯示格式:全部欄位
共 3 筆
------------------------------------------------------------------------ 第 1 筆 ---------------------------------------------------------------------
系統識別號 U0026-0812200910243004
論文名稱(中文) 預測茶鹼用於治療早產兒呼吸暫停之藥物血中濃度
論文名稱(英文) predictability of serum theophylline level in preterm infants with apnea
校院名稱 成功大學
系所名稱(中) 臨床藥學研究所
系所名稱(英) Institute of Clinical Pharmacy
學年度 90
學期 2
出版年 91
研究生(中文) 鄭靜蘭
學號 s6689101
學位類別 碩士
語文別 中文
口試日期 2002-07-17
論文頁數 138頁
口試委員 指導教授-林其和
口試委員-高雅慧
口試委員-周辰熹
口試委員-蘇聖芳
關鍵字(中) 族群藥動模式
血中濃度
早產兒
呼吸暫停
茶鹼
關鍵字(英) Population pharmacokinetics
Theophylline
Apnea
Preterm infants
Serum concentrations
學科別分類
中文摘要 中文摘要
呼吸暫停為早產兒常見的問題之一。主要是早產兒中樞及呼吸系統發育不良所造成。這疾病的治療包括藥物及非藥物治療,在我們院內首選的治療藥物為aminophylline(內含85 % theophylline茶鹼)。Theophylline為治療指數狹窄的藥品,用於治療早產兒呼吸暫停的建議血中濃度範圍為6 ~ 13 mg/ml。Theophylline在早產兒已有個體及族群的藥物動態學研究。
本研究主要的目的為套用Moore 等人研究之theophylline族群藥動模式,評估早產兒的藥動參數,之後依據估算的藥動參數,給予適當的建議劑量,並預測其血中濃度,以減少抽血次數並瞭解本院新生兒加護病房使用theophylline治療呼吸暫停的效果、副作用以及血中藥物濃度的關係。
本研究主要分為兩個部分:首先,評估theophylline族群藥動模式,共收集92位新生兒曾使用過theophylline且至少有監測過一次血中濃度,共有429個血中濃度數值。平均懷孕週數及平均出生體重分別為28.6 ± 2.7 週,1,244 ± 0.48 公克。套用模式後所得的平均清除率為0.0309 ± 0.012 L/hr,範圍為0.0095~0.0929 L/hr。出生時有窒息情況的新生兒平均清除率較出生時無窒息情況的新生兒減少了8 %。研究中發現清除率與出生後的正確週數關係較出生後天數好。而給藥劑量與血中濃度呈非線性關係且血中濃度大於15 mg/ml者皆發生在出生後3週內。預估的濃度曲線下面積(AUC)與濃度之間的相關性 (AUC = Dose / CL),利用出生後正確體重較出生體重相關性較佳。Pearson Correlation Coefficients: 0.54 vs. 0.45, p <0.0001, Linear Regression: r2 = 0.29 vs. 0.21, p < 0.0001。最後新的方程式為:Dose/CL (mg/kg/day)/(L/hr) = 6.6708 Conc. (mg/ml) + 14.971(Conc. = Concentration)。
接著,前瞻性收集了22位新生兒共有133個theophylline血中濃度數值,平均懷孕週數及平均出生體重分別為27.8 ± 1.9 週,1,096 ± 0.31公克。清除率為0.03 ± 0.13 L/hr。所有22位新生兒的殘差值介於-4 ~ -3 mg/ml佔最多部分,而觀察值與預估值的平均錯誤百分比(錯誤百分比 = % [觀察值-預估值] ÷觀察值)為-14.9 %,範圍為1.2 ~ 228 %。在2位早產兒共有3個血中濃度的數值其觀察值及預估值的殘差值在10單位以上者是因在一週內體重變化為24 %的緣故。出生體重小於1,000公克、給藥間隔為q8h及抽血前1天調整劑量者皆會影響預估的血中濃度數值。
在本院新生兒加護病房,自90年12月至91年5月共觀察了24位新生兒theophylline血中濃度與療效及副作用之間的關係。呼吸暫停的發生次數以護理人員記錄為主,在血中濃度為6 ~ 13 mg/ml 時有79 % 的新生兒達治療成功的標準。心跳過快為最常見的副作用,其中有3位因持續性心跳過快而停藥。
總之,因給藥劑量與血中濃度的非線性關係及清除率的變異性大,並無法依據Moore等人研究所得的公式預估本院新生兒正確的藥物血中濃度。正確的給藥劑量及抽血時間點是主要的關鍵。然而theophylline明顯可降低早產兒呼吸暫停的發生次數,適當的療效濃度為6 ~ 13 mg/ml,心跳過快為最常見的副作用。
英文摘要 英文摘要
Apnea of prematurity is a common problem in premature infants. It is related to immaturity of the infant’s neurologic and respiratory systems. Management of apnea of prematurity involves both pharmacological and nonpharmacological treatment, and aminophyllin (contain 85 % theophylline) is the first-line choice in our hospital. The range of effective theophylline serum concentrations is relatively narrow and generally ranged between 6 and 13 mg/ml. The pharmacokinetics of theophylline in premature infants have been studied using either individual analysis methods or population methods.
The aim of the study was to estimate the pharmacokinetic parameters, clearance rate (CL) using the population pharmacokinetic models proposed by Moore et al. Based on the validated population models, serum theophylline level was predicted to reduce the frequency of blood sampling. The relationship between theophylline concentrations and it’s efficacy or adverse effects was also evaluated.
This study consisted of two parts. We first evaluated the population pharmacokinetics models of theophylline using 429 theophylline serum concentration measurements from 92 neonates receiving theophylline and measured theophylline serum concentration at least once. Mean ± SD gestational age and birth weight were 28.6 ± 2.7 wks and 1,244 ± 0.48 g, respectively. The clearance (CL) in the study population was 0.0309 ± 0.012 L/hr (mean ± SD), ranged 0.0095~0.0929 L/hr. Newborns who had experienced birth asphyxia had a mean theophylline clearance 8% lower than nonasphyxiated newborns. Our findings indicate that postconceptional age rather than postnatal age is a better reference during theophylline therapy in premature infants. Theophylline plasma concentrations increased in a nonlinear proportion to the dosage, and most plasma concentrations over 15 mg/ml occurred in the first three weeks of life. Relationship between estimate area under concentration curve (AUC = Dose / CL) and concentration using current weight is better than birth weight (Pearson Correlation Coefficients: 0.54 vs. 0.45, p <0.0001, Linear Regression: r2 = 0.29 vs. 0.21, p < 0.0001). The final new models were: Dose/CL (mg/kg/day)/(L/hr) = 6.6708 Conc. (mg/ml) + 14.971(Conc. = Concentration).
Predictive performance of the new population models was prospectivly evaluated on another group of 22 infants, with Mean ± SD gestational age and birth weight as 27.8 ± 1.9 wks and 1,096 ± 0.31 g, respectively. Clearance was 0.03 ± 0.13 L/hr (mean ± SD). The residue of -3 to -4 mg/ml was obtained and in the majority of in the study. Error percentage (% Error = % measured – expected /measured) was -14.9 % (mean), ranged 1.2 ~ 228 %. Discrepancy greater than 10 mg/ml was observed in three premature infants because of more than 24 % loss of body weight within 1 week of life. Birth weight less than 1,000 g, dosing interval of every eight hour, and change of dose one day before sampling, were three major factors affecting the predicted serum concentrations.
Then, we conducted a prospective, routine monitoring to evaluate the correlation between efficacy or adverse effect and theophylline serum concentrations in 24 premature infants. Data were collected from premature infants treated with aminophylline from December 2001 through May 2002. Apnea was detected from nursing records, and the success rate of aminophylline treatment was 79 %, with serum concentrations of 6 to 13 mg/ml. The most common side effect was tachycardia, and theophylline was discontinued due to persistent tachycardia in three patients.
In brief, there was a nonlinear correlation between dose and plasma concentrations, and plasma theophylline clearance was unpredictable according to the population pharmacokinetic models proposed by Moore et al. Theophylline effectivnely decreases apnea of prematurity at plasma concentration of 6 – 13 mg/ml, and monitoring of serum theophylline levels is mandatory.
論文目次 目錄 頁碼
中文摘要 I
英文摘要 III
縮寫表 VI
目錄 VII
表目錄 XI
圖目錄 XII
第壹章 研究背景 1
第貳章 文獻回顧 3
第一節 早產兒呼吸暫停的定義、發生率及病態生理學 3
1.1 定義(Definition) 3
1.2 呼吸暫停之分類 (Classification) 3
1.3 發生率(Incidence) 4
1.4 病因(Etiology) 5
1.5 病態生理學(Pathophysiology) 6
第二節 早產兒呼吸暫停之非藥物治療 10
第三節 早產兒呼吸暫停之藥物治療 14
3.1 甲基黃嘌呤類(Methylxanthines) 14
3.1.1 Theophylline 14
3.1.1-1 Theophylline用於早產兒呼吸暫停之建議劑量 16
3.1.2 Caffeine 19
3.1.2-1 Caffeine用於早產兒呼吸暫停之建議劑量 20
3.1.3 Theophylline及Caffeine之副作用 22
頁碼
3.1.4 Theophylline與Caffeine的比較 23
3.1.5 Theophylline與CPAP的比較 25
3.2 Doxapram 25
3.3 其他(others) 26
第四節 早產兒呼吸暫停之預後 27
第五節 Theophylline在新生兒之藥理及生理作用 29
5.1 Theophylline在新生兒之藥理作用 30
5.1.1 Theophylline之一般藥理作用 30
5.1.2 Theophylline之作用機轉 31
5.1.3 Theophylline在新生兒的藥理及生理作用 32
第六節 Theophylline在早產兒之代謝 34
第七節 Theophylline在早產兒之藥物動態學研究 38
第八節 Theophylline的血中濃度監測 42
第九節 影響theophylline血中濃度的因子 43
9.1 Theophylline之吸收 43
9.2 Theophylline之蛋白結合及分佈體積 43
9.3 Theophylline生物轉化(biotransformation) 44
9.3.1 內在因子 44
9.3.2 外在因子 45
第十節 總結 48
第參章 研究目的 49
第肆章 研究方法 50
頁碼
第一節 研究設計 50
4.1. 研究對象 50
4.2 藥品 51
4.3 臨床評估 51
4.4國外族群藥動模式之公式 52
第二節 研究流程 53
第三節 統計分析 56
第伍章 研究結果 57
第一節 研究對象 57
第二節 Theophylline監測情況 62
第三節 計算公式 66
第四節 預測血中濃度 69
第五節 臨床療效及副作用評估 73
第陸章 討論 75
第一節 研究對象與血中濃度監測情況 75
第二節 計算公式與預測血中濃度 78
第三節 臨床療效及副作用評估 83
第柒章 結論 85
參考文獻 87
附錄一 病患記錄表格 101
附錄二 臨床藥事服務 102
第一節 藥物不良反應(Adverse effect)之評估 103
頁碼
第二節 藥物諮詢 107
2.1 藥物血管外滲之處理 107
2.2 早產兒慢性肺疾病之類固醇選擇 109
2.3 早產兒上消化道出血之藥物治療 111
2.4 早產兒使用cisapride用於治療餵食困難(feeding intolerance)
的療效及安全性 113
2.5 Hypoventilation syndrome的藥物治療 115
2.6 新生兒Gentamicin的使用劑量 117
第三節 藥物使用評估 120
3.1 新生兒加護病房全身性黴菌感染之藥物治療 120
3.2 早產兒使用erythromycin 125

表目錄 頁碼
表一 美國食品及藥物管理局公布theophylline之劑量準則 2
表二 呼吸暫停之評估 10
表三 原發性早產兒呼吸暫停之非藥物治療 13
表四 Theophylline在不同年齡層的藥動參數 17
表五 Theophylline用於呼吸暫停及拔除呼吸器的建議劑量 19
表六 Caffeine用於早產兒呼吸暫停的藥動參數 21
表七 Caffeine在新生兒半衰期的變化 21
表八 Theophylline副作用與血中濃度的關係 22
表九 Theophylline與Caffeine在新生兒常見的副作用 23
表十 Theophylline與Caffeine 的藥理作用比較 24
表十一 Theophylline與Caffeine 用於治療早產兒呼吸暫停之比較 24
表十二 建議出院後監測心肺功能的適應症 27
表十三 Theophylline在新生兒的藥物動態學研究 38
表十四 在早產兒維持血中濃度10 mg/ml之theophylline的劑量 40
表十五 Theophylline抽血時間點 42
表十六 影響Theophylline蛋白結合的藥品 44
表十七 疾病對theophylline藥動參數的影響 46
表十八 影響Theophylline血中濃度的藥物 47
表十九 92位及22位新生兒的基本資料 58
表二十 24 位新生兒theophylline臨床療效及血中濃度 74
表二十一 92位新生兒基本資料與其他文獻的比較 80
表二十二 92位新生兒清除率與文獻的比較 82
附錄表格 124

圖目錄 頁碼
圖2.1 呼吸暫停之型態在早產兒出生後的改變 4
圖2.2 影響正常呼吸功能之因素 9
圖2.3 治療呼吸暫停之建議流程 28
圖2.4 Xanthine與Theophylline結構式 29
圖2.5 Theophylline的生理作用 30
圖2.6 Theophylline及Caffeine的代謝路徑 35
圖2.7 Theophylline在新生兒與成人的代謝 36
圖2.8 Caffeine在新生兒與成人的代謝 37
圖4.1 研究流程圖之一 54
圖4.2 研究流程圖之二 55
圖 5.1 92位早產兒懷孕週數分佈情形 60
圖 5.2 92位早產兒出生體重分佈情形 61
圖 5.3 92位新生兒開始使用theophylline的時間 63
圖 5.4 92位新生兒使用theophylline後緩解的時間 63
圖 5.5 92位新生兒之懷孕週數與治療天數 64
圖 5.6 92位早產兒測得之thephylline血中濃度 64
圖 5.7 92位早產兒theophylline血中濃度之分佈情形 65
圖 5.8 92位新生兒theophylline血中濃度與劑量的關係 65
圖 5.9 92位新生兒theophylline血中濃度與Dose/CL 的關係 67
圖5.10 69位新生兒theophylline血中濃度與Dose/CL 的關係 68
圖 5.11 22位新生兒theophylline血中濃度的預估值與觀察值 70
圖5.12 22 位新生兒血中濃度觀察值與預測值的殘差值 71
頁碼
圖 5.13 22位新生兒觀察值與預估值殘差值的分佈 72
圖5.14 22位新生兒血中濃度觀察值與預測值之錯誤百分比 72
圖 6.1 92位新生兒懷孕週數與清除的關係 80
圖 6.2 92位新生兒出生後正確週數與清除率的關係 81
圖 6.3 92位新生兒出生後天數與清除率之關係 81
參考文獻 參考文獻
1. Alden ER, Mandelkorn T, Woodrum DE, Wennberg RP, Parks, CR, and Hodson WA. Morbidity and mortality of infants weighing less than 1,000 grams in an intensive care nursery. Pediatrics 1972;50:40-9.
2. Aldridge A, Aranda JV, and Neims AH. Caffeine metabolism in the newborn. Clin Pharmacol Ther 1979;25:447-53.
3. Al-Omran A, and Al-Alaiyan S. Theophylline concentration following equal doses of intravenous aminophylline and oral theophylline preterm infants. Am J Perintol 1997;14:147-9.
4. Anderson JL, Ayres JW, and Hall CA. Potential pharmacokinetic interaction between theophylline and prednisone. Clin Pharmacy 1984;3:187-9.
5. Aranda JV. Letter: Metabolic effect of theophylline in the premature neonate. J Pediatr 1976;89:833-4.
6. Aranda JV, Sitar DS, Parsons WD, Loughnan PM, and Neims AH. Pharmacokinetic aspects of theophylline in premature newborns.
N Engl J Med 1976;295:413-6.
7. Aranda JV, Cook CE, Gorman W, Coolinge JM, Loughnan PM, and Outerbridge EW et al. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr 1979;94:663-8.
8. Aranda JV, Chemtob S, Laudignon N, and Sasyniuk BI. Pharmacologic effects of theophylline in the newborn. J Allergy Clin Immunol 1986;78:773-80.
9. Bairam A, Boutroy M-J, Badonnel Y, and Vert P. Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. J Pediatr 1987;110:636-9.
10. Barbé F, Hansen C, Badonnel Y, Legagneur H, Vert P, and Boutroy M-J. Severe side effects and drug plasma concentrations in preterm infants treated with doxapram. Ther Drug Monit 1999;21:547-52.
11. Barett CT, Sevanian A, and Lavin N. Role of adenosine 3’ 5’ monophosphate in maturation of fetal lungs. Pediatr Res 1976;10:621-5.
12. Barrington K, Finer NN, Peter KL, and Barton J. Physiologic effects of doxapram in idiopathic apnea of prematurity. J Pediatr 1986;108:125-9.
13. Barrington K, and Finer N. The natural history of the appearance of apnea of prematurity. Pediatr Res 1991;29:372-5.
14. Barrington KJ, and Finer NN. A randomized controlled trial of aminophylline in ventilatory weaning of premature infants. Crit Care Med 1993;21:846-50.
15. Bednarek FJ, and Roloff DW. Treatment of apnea of prematurity with aminophylline. Pediatrics 1976;58:335-9.
16. Bernstein PS. Conference: Society of maternal-fetal medicine -Risks and benefits of antenatal corticosteroids.
17. Bhatia J. Current options in the management of apnea of prematurity. Clin Pediatr 2000;39:327-36.
18. Bhatt-Mehta V, Johnson CE, Donn SM, Spadoni V, and Schork MA. Accuracy and reliability of dosing equations to individualize theophylline treatment of apnea of prematurity. Pharmacotherapy 1995;15:246-50.
19. Bhatt-Mehta V, Donn SM, Schork A, Reed S, and Johnson CE. Prospective evaluation of two dosing equations for theophylline in premature infants. Pharmacotherapy 1996;16:769-76.
20. Blanchette VS, and Zipursky A. Assessment of anemia in newborn infants. Clin Perinatol 1984;11:489-510.
21. Bonati M, Latini R, Marra G, Assael BM, and Parini R. Theophylline metabolism during the first month of life and development. Pediatr Res 1981;15:304-8.
22. Bower LK, Barnhart SL, Betit P, clink J, Hendon B, Masi-Lynch J, and Wilson BG. Application of continuous positive airway pressure to neonates via nasal prongs or nasopharyngeal tube. AARC clinical practice guideline. Respir Care 1994;39:817-23.
23. Brouard C, Moriette G, Murat I, Flouvat V, Pajot N, and Walti H et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. AJDC 1985;139:689-700.
24. Butcher-P MC, Henderson-S DJ, Holley D, Lacey JL, and Edwards DA. Relation between apnoea duration and type and neurological status of preterm infants. Arch Dis Child 1985;60:953-8.
25. Calhoun LK. Pharmacologic management of apnea of prematurity. J Perinat Neonatal Nurs 1996;9:56-62.
26. Carnielli VP, Verlato G, Benini F, Rossi K, Cavedagni M, and Filippone M et al. Metabolic and respiratory effects of theophylline in the preterm infant. Arch Dis Child Fetal Neonatal Ed 2000;83:F39-43.
27. Cartaya EB, Pathak A, Lhamm C, and Eyal FG. Effect and safety of doxapram. Pediatr Reasearch 1989;25:305A.
28. Chaudhuri M, Garg SK, Narang A, and Bhakoo ON. Kinetics of theophylline in apnea of prematurity in small for gestational age babies. Idian Pediatr 1996;33:181-7.
29. Collart L, Blaschke TF, Boucher F, and Prober CG. Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. Dev Pharmacol Ther 1992;18:71-80.
30. Conlon PF, Grambau GR, Johnson CE, and Weg JG. Effect of intravenous furosemide on serum theophylline concentration. Am J Hosp Pharm 1981;38:1345-7.
31. Consensus statement: national institutes of health consensus development conference on infantile apnea and home monitoring, Sept 29 to Oct 1, 1986. Pediatrics 1987;79:292-9.
32. Corbet AJS, Flax P, and Alston C. Effect of aminophylline and dexamethasone on secretion of pulmonary surfactant in fetal rabbits. Pediatr Res 1978;12:797-9.
33. Cordoba E, Gerhardt T, Rojas M, Duara S, and Bancalari E. Comparison of the effects of acetazolamide and aminophylline on apnea incidence and on ventilatory response to CO2 in preterm infants. Peditr Pulmonol 1994;17:291-5.
34. Daily WJ, Klaus M, and Meyer HB. Apnea in premature infants: monitoring, incidence, heart rate changes, and an effect of environmental temperature. Pediatrics 1969;43:510-8.
35. Dani C, Bertini G, Reali M, Tronchin M, Wiechmann L, and Martelli E et al. Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment. Biol Neonate 2000;78:27-32.
36. Davi MJ, Sankaran K, Simons KJ, Simons FR. Seshia MM, and Rigatto H. Physiologic changes induced by theophylline in the treatment of apnea in preterm infants. J Pediatr 1978;92:91-5.
37. Davis P, Doyle L, Rickards A, Kelly E, Ford G, and Davis NM et al. Methylxanthines and sensorineural outcome at 14 years in children < 1501 g birthweight. J Pediatr Child Health 2000;36:47-50.
38. Diderholm B, Ewald U, and Gustafsson J. Effect of theophylline on glucose production and lipolysis in preterm infants (£ 32 weeks). Pediatr Res 1999;45:674-9.
39. Durand DJ, Goodman A, Ray P, Ballard RA, and Clyman RI. Theophylline treatment in the extubation of infants weighing less than 1,250 grams: a controlled trial. Pediatrics 1987;80:684-8.
40. Eichenwald EC, Aina A, and Stark AR. Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. Pediatrics 1997;100:354-9.
41. Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM and Wynne BA et al. Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study. Pharmacotherapy 2000;20:644-52.
42. Ergusson RJ, Scott CM, Rafferty P, and Gaddie J. Effect of prednisolone on theophylline pharmacokinetics in patients with chronic airflow obstruction. Thorax 1987;42:195-8.
43. Fjeld CR, Cole FS, and Bier DM. Energy expenditure, liposis, and glucose production in preterm infants treated with theophylline. Pediatr Res 1992;32:693-8.
44. Gal P, Roop C, Robinson H, and Erkan NV. Theophylline-induced seizures in accidentally overdosed neonates. Pediatrics 1980;65:547-9.
45. Gal P, and Ravenel SD. Editor: Extubation of infants with respiratory distress syndrome using aminophylline. J Pediatr 1984;104:485-6.
46. Gal P, and Gilman JT. Concerns about the food and drug administration guidelines for neonatal theophylline dosing. Ther Drug Monit 1986;8:1-3
47. Gaultier Cl. Apnea and sleep state in newborns and infants. Biol Neonate 1994;65:231-4.
48. Gerhardt T, McCarthy J, and Bancalari E. Effect of aminophylline on respiratory center activity and metabolic rate in premature infants with idiopathic apnea. Pediatrics 1979;63:537-42.
49. Gerhardt T, and Bancalari E. Apnea of prematurity: I. Lung function and regulation of breathing. Pediatrics 1984;58-62.
50. Gilman JT, Gal P, Levine RS, Hersh GB, and Erkan NV. Factors influencing theophylline disposition in 179 newborns. Ther Drug Monit 1986;8:4-10.
51. Gittermann MK, Fusch C, Gittermann AR, Regazzoni BM, and Moessinger AC. Early nasal continuous positive airway pressure treatment reduces the need for intubation in very low birth weight infants. Eur J pediatr 1997;156:384-8.
52. Guennec J-C L, Billon B, and Pare C. Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gesatation age, hepatic disease, and breast-feeding. Pediatrics 1985;76:834-40.
53. Gunn TR, Metrakos K, Riley P, Willis D, and Aranda JV. Sequelae of caffeine treatment in preterm infants with apnea. J Pediatr 1979;94:106-9.
54. Harris MC, Baumgart S, Rooklin AR, and Fox WW. Successful extubation of infants with respiratory distress syndrome using aminophylline. J Pediatr 1983;103:303-5.
55. Hascoet JM, Hamon I, and Boutroy MJ. Risks and benefits of therapies for apnoea in premature infants. Drug Safety 2000;23:363-79.
56. Hendeles L, Massanari M, Weinberger M. Theophylline. In: Evans WE, Schentag JJ, and Jusko WJ. eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. 2nd ed. Spokane, Applied Therapeutics Inc.;1986:1105-88.
57. Hodgman JE, Gonzalez F, Hoppenbrouwers T, and Cabal LA. Apnea, transient episodes of bradycardia, and periodic breathing in preterm infants. AJDC 1990;144:54-7.
58. Hogue SL, and Phelps ST. Evaluation of three theophylline dosing equations for use in infants up to one year of age. J Pediatr 1993;123:651-6.
59. Holditch-D D, Edwards LJ, and Wigger MC. Pathologic apnea and brief respiratory pauses in preterm infants: relation to sleep state. Nursing Res 1994;43:293-300.
60. Hufnal-M CA, Blackmon L, Baumgart S, and Pereira GR. Enteral theophylline and necrotizing enterocolitis in the low-birthweight infant. Clin Pediatr 1993:647-52.
61. Janicke UA, KrÜdewagen B, Schulz A, and Gundert-R U. Absence of a clinically significant interaction between theophylline and furosemide. Eur J Clin Pharmacol 1987;33:487-91.
62. Jones RA-K. Dosage schedule for intravenous aminophylline in apnoea of prematurity, base on pharmacokinetic studies. Arch Dis Child 1979;54:190-3.
63. Jones RA-K. A controlled trial of a regularly cycled oscillating waterbed and a non-oscillating waterbed in the prevention of apnoea in the perterm infant. Arch Dis Child 1981;56:889-91.
64. Jones RA-K. Apnoea of immaturity: a controlled trial of theophylline and face mask continuous positive airways pressure. Arch Dis Child 1982;57:761-5.
65. Jordan GD, Themelis NJ, Messerly SO, Jarrett RV, Garcia J, and Frank G. Doxapram and potential benzyl alcohol toxicity: a moratorium on clinical ivestigation? Pediatrics 1986;78:540-1.
66. Kandrotas RJ, Cranfield TL, Gal P, Ransom JL, and Weaver RL. Effect of phenobarbtial administration on theophylline clearance in premature neontes. Ther Drug Monit 1990;12:139-43.
67. Karlsson MO, Thomson AH, McGovern EM, Chow P, Evans TJ, and Kelman AW. Population pharmacokinetics rectal theophylline in neonates. Ther Drug Monit 1991;13:195-200.
68. Kattwinkel J, Nearman HS, Fanaroff AA, Katona PG, and Klaus MH. J Pediatr 1975;86:588-92.
69. Khalaf MN, Brodsky N, Hurley J, and Bhandari V. A prospective randomized, controlled trial comparing synchronized nasal intermittent positive pressure ventilation verus nasal continuous positive airway pressure as modes of extubation. Pediatrics 2001;108:13-7.
70. Kitchen WH, Yu VH, Orgill AA, Ford GF, Rickards A, and Astury J et al. Collaborative study of very-low-birth-weight infants. Am J Dis Child 1983;137:555-9.
71. Klesh KW, Brozanski BS, and Guthrie RD. Apnea of prematurity: current theories of pathogenesis and treatment. In: Guthrie RD ed. Neonatal intensive care 1st ed, Churchill Livingstone Inc;1988: 91-122.
72. Korner AF, Kraemer HC, Haffner ME, and Cosper LM. Effects of waterbed flotation on premature infants: a pilot study. Pediatrics 1975;56:361-7.
73. Korner AF, Guilleminault C, Hoed JV, and Baldwin RB. Reduction of sleep apnea and bradycardia in preterm infants on oscillating water beds: a controlled polygraphic study. Pediatrics 1978;61:528-33.
74. Korner AF, Ruppel EM, and Rho JM. Effects of water beds on the sleep and motility of theophylline-treated preterm infants. Pediatrics 1982;70:864-9.
75. Kraus DM, Fischer JH, Reitz SJ, Kecskes SA, Yeh TF, and McCuuloch KM et al. Alteractions in theophylline metabolism during the first year of life. Clin Pharmacol Ther 1993;54:351-9.
76. Kraus DM, Hatzopoulos FK, Reitz SJ, and Fischer JH. Pharmacokinetic evaluation of two theophylline dosing methods for infants. Ther Drug Monit 1994;16:270-6.
77. Krauss AN. Apnea in infancy: pathophysiology, diagnosis, and treatment. NY State J Med 1986;Feb:89-96.
78. Kriter KE, and Blanchard J. Therapy review: management of apnea in infants. Clin Pharm 1989;8:577-87.
79. Kurz H. Influence of nasopharyngeal CPAP on breathing pattern and incidence of apnoeas in preterm infants. Biol Neonate 1999;76:129-33.
80. Kuzemko JA, Paala J. Apnoeic attacks in the newborn treated with aminophylline. Arch Dis Child 1973;48:404-6.
81. Lagercranta H, Rane A, and Tunell R. Plasma concentrations-effect relationship of theophylline in treatment of apnea in preterm infants. Eur J Clin Pharmacol 1980;18:65-8.
82. Lee D, Caces R, Kwiatkowski K, Cates D, and Rigatto H. A developmental study on types and frequency distribution of short apneas(3 to 15 seconds) in term and preterm infants. Pediatr Res 1987;22:344-9.
83. Lee TC, Charles BG, Steer PA, Flenady VJ, and Grant TC. Theophylline population pharmacokinetics form routine monitoring data in very premature infants with apnoea. Br J Clin Pharmacol 1996;41:191-200.
84. Lesko LJ. Dose-dependent kinetics of theophylline. J Allergy Clin Immunol 1986;78:723-7.
85. Lin CH. Wang ST, Lin YJ, and Yeh TF. Efficacy of nasal intermittent positive pressure ventilation in treating apnea of prematurity. Pediatr Pulmonol 1998;26:349-53.
86. Loughnan PM, and Namara JM. Paroxysmal supraventricular tachycardia during theophylline therapy in a premature infant. J Pediatr 1978;92:1016-8.
87. Marchal F, Bairam A, and Vert P. Neonatal apnea and apneic syndromes. Clin Perintol 1987;14:509-29.
88. Marquis JF, Carruthers SG, Spence JD, Brownstone YS, and Toogood JH. Phenytoin-theophylline interaction. N Engl J Med 1981;307:1189-90.
89. McNamara F, and Sullivan CE. Obstructive sleep apnea in infants and its management with nasal continuous positive airway pressure. Chest 1999;116:10-6.
90. Miller CA, Gaylord M, and Lorch M. The use of primidone in neonates with theophylline-resistant apnea. Am J Dis Child 1993;147:183-6.
91. Miller MJ, Carlo WA, and Martin RJ. Continuous positive airway pressure selectively reduces obstructive apnea in preterm infants. J pediatr 1985;106:91-4.
92. Miller MJ, and Martin RJ. Apnea of permaturity. Clin Perinatol 1992;19:789-807.
93. Miller CA, Caylord M, Lorch M. The use of primidone in neonates with neonates with theophylline-resistant apnea. Am J Dis Child 1993;147:183-6.
94. Milner AD, Boon AW, Saunders RA, and Hopkin IE. Upper airways obstuction and apnoea in preterm babies. Arch Dis Child 1980;55:22-5.
95. Moore ES, Faix RG, Banagale RC, and Grasela TH. The population pharmacokinetics of theophylline in neonates and young infants. J Pharmacokin Biopharm 1989;17:47-65.
96. Murat I, Moriette G, Bilin MC, Couchard M, Flouvat B, and Gamarra ED et al. The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. J Pediatr 1981;99:984-9.
97. Murphy JE. New FDA guidelines for therophylline dosing in infants. Clinical pharmacy 1986;5:16.
98. Muttitt SC, Tierney AJ, and Finer NN. The dose response of theophylline in the treatment of apnea of prematurity. J Pediatr 1988;112:115-21.
99. Myers TF, Milsap RL, Krauss AN, Auld PA-M, and Reidenberg MM. Low-dose theophylline therapy in idiopathic apnea of prematurity. J Pediatr 1980;96:99-103.
100. Nassif EG, Weinberger MM, Shannon D, Guiang SF, Hendelex L, and Jimenez D et al. Theophylline disposition in infancy. J Pediatr 1981;98:158-61.
101. Nobel PA, and Light GS. Theophylline-induced diuresis in the neonate. J Pediatr 1977;90:825-6.
102. Papageorgiou A, and Bardin CL. The extremely-low-birth-weight infants: apnea of prematurity. In: Avery GB ed. Neonatology: pathophysiology and management of the newborn. 5th ed. Philadelphia: Lippincott Williams&Wilkins companies;1999:464.
103. Peabody JL, Neese AL, Philip GS, Lucey JF, and Soyka LF. Transcutaneous oxygen monitoring in aminophylline-treated apneic infants. Pediatrics 1978;62:698-701.
104. Peliowski A, and Finer NN. A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. J Pediatr 1990;116:648-53.
105. Persson CA. Overview of effects of theophylline. J Allergy Clin Immunol 1986;78:780-7.
106. Pesce AJ, Rashkin M, and Kotagal U. Standards of laboratory practice: theophylline and caffeine monitoring. Clin Chem 1998;44:1124-8.
107. Powell EC, Reynolds SL, and Rubenstein JS. Theophylline toxicity in children: A retrospective review. Pediatr Emer Care 1993;9:129-3.
108. Preez MJ, Botha JH, McFadyen ML, and Holford NG.The pharmacokinetics of theophylline in premature neonates during the first few days after birth. Ther Drug Monit 1999;21:598-603.
109. Reese J, Prentice G, and Yu VY-H. Dose conversion from aminophylline to theophylline in preterm infants. Arch Dis Child 1994;71:F51-2.
110. Resar RK, Fritz WL, Perry DF, and Barbee RA. Kinetics of theophylline: variability and effect of arterial pH in chronic obstructive lung disease. Chest 1979;76:11-6.
111. Rigatto H, and Brady JP. Periodic breathing and apnea in preterm infants: II. Hypoxia as a primary event. Pediatrics 1972;50:219-27.
112. Rigatto H, Brady JP, and Verduzco R-T. Chemoreceptor reflexes in preterm infants: I. The effect of gestational and postnatal age on the ventilatory response to inhalation of 100% and 15% oxygen. Pediatrics 1975;55:604-13.
113. Rigatto H, Brady JP, and Verduzco R-T. Chemoreceptor reflexes in pretem infants: II. The effect of gestational and postnatal age on the ventilatory response to inhaled carbon dioxide. Pediatrics 1975;55:614-20.
114. Robertson NJ, Hamilton PA. Randomised trial of elective continuous positive airway pressure (CPAP)compared with rescue CPAP after extubation. Arch Dis Child Fetal Neonatal Ed 1998;79:F58-60.
115. Rosenkrantz TS, and Oh W. Aminophylline reduces cerebral blood flow velocity in low birth weight infants. Am J Dis Child 1984;138:489
116. Ruggins NR. Pathophysiology of apnoea in preterm infants. Arch Dis Child 1991;66:70-3.
117. Ryan CA, Finer NN, and Peter KL. Nasal intermittent positive-pressure ventilation offers no advantages over nasal continuous positive airway pressure in apnea of prematurity. AJDC 1989;143:1196-8.
118. Scanlon JM, Chin KC, Morgan MI, Durbin GM, Hale KA, and Brown SS. Caffeine or theophylline for neonatal apnoea?. Arch Dis Child 1992;67:425-8.
119. Schmidt B. Methylxanthine therapy in premature infants: Sound practice, disaster, or fruitless byway?. J Pediatr 1999;135:526-8.
120. Schulte FJ, Busse C, and Eichorn W. Rapid eye movement sleep, motoneurone inhibition, and apneic spells in preterm infants. Pediatr Res 1977;11:709-13.
121. Shannon DC, Gotay F, Stein IM, Rogers MC, Todres ID, and Moylan FM. Pediatrics 1975;55:589-94.
122. Sheiner LB, Rosenberg B, and Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokin Biopharm 1977;5:445-79.
123. Sims ME, Yau G, Rambhatla S, Cabal L, Wu P Y-K. Limitations of theophylline in the treatment of apnea of prematurity. AJDC 1985;139:567-70.
124. Sims ME, Rangasamy R, Lee S, Chung H, Cohen J, and Walther FJ. Coomparative evaluation of caffeine and theophylline for weaning premature infants from the ventilator. Am J Perinatol 1989;6:72-5.
125. Stonestreet BS, Nowicki PT, and Hansen NB. Effect of aminophylline on brain blood flow in the newborn piglet. Dev Pharmacol Ther 1983;6:248.
126. Srinivasan G, Pildes RS, and Jaspan JB. Metabolic effects of theophylline in premature infants. J Pediatr 1981;98:815-7.
127. Tatro DS ed. Theophylline-corticosteroids. In: Drug Interaction Facts, St. Louis, Wolters Kluwer company. 2002:1248.
128. Toback JW, and Gilman ME. Theophylline-furosemide inactivation? Pediatrics 1983;71:140-1.
129. Tröger U and Meyer FP. Influence of endogenous and exogenous effectors on the pahrmacokinetics of theophylline. Clin Pharmacolinet 1995;28:287-314.
130. Tserng KY, Takieddine FN, and King KC. Developmental aspects of theophylline metabolism in premature infants. Clin Pharmacol Ther 1983;33:522-8.
131. Tuck SJ, Monin P, Duvivier C, May T, and Vept P. Effect of a rocking bed on apnoea of prematurity. Arch Dis Child 1982;57:475-7.
132. Uauy R, Shapiro DL, Smith B, and Warshaw JB. Pediatrics 1975;55:595-8.
133. Undem BJ and Lichtenstein LM. Drugs used in the treatment of asthma:theophylline. In: Hardman JG and Limbird LE ed. Goodman & Gilman’s the pharmacological basis of therapeutics, 10th ed. McGraw-Hill, New York;2002:743-7.
134. Upton CJ, Milner AD, and Stokes GM. Upper airway patency during apnoea of prematurity. Arch Dis Child 1992;67:419-24.
135. Vallener JJ, Speir WA, Kolbeck RC, Harrison GN, and Bransome
ED. Effect of pH on the binding of theophylline to serum proteins. Am Rev Resp Dis 1979;120:83-6.
136. Vassallo R, and Lipsky JJ. Theophylline: Recent advances in the understanding of its mode of action and uses in clinical practice. Mayo Clin Proc 1998;73:346-54.
137. Vaucher Y, Lightner ES, and Walson PD. Theophylline poisoning. J Pediatr 1977;90:827-30.
138. Verder H, Robertson B, Greisen G, Ebbesen F, Albertsen P, and Lundstrom K et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N Engl J Med 1994;331:1051-5.
140. Viscardi RM, Faix RG, Nicks JJ, and Grasela TH. Efficacy of theophylline for prevention of post-extubation respiratory failure in very low birth weight infants. J Pediatr 1985;107:469-72.
141. Yazdani M, Kissling GE, Tran TH, Gottschalk SK, and Schuth CR. Phenobarbital increases the theophylline requirement of premature infants being treated for apnea. AJDC 1987;141:97-9.
142. Yeh TF. Apnea. In: Neonatal Therapeutics, 2nd ed.St. Louis, MO:Mosby-Year Book, Inc.;1991:40-53.
143. Zanardo V, Dani C, Trevisanuto D, Meneghetti S, Guglielmi A, Zacchello G, Cantaruti F. Methylxanthines increase renal calcium excretion in preterm infants. Biol Neonate 1995;68:169-74.
144. 王文憲 譯,呼吸的控制,人體生理學,合記,第六版pp. 639-52.,1994。
145. 傅祖慶 林富美 林則彬 賴亮全 等人譯,肺換氣的機轉,蓋統生理學-生理及疾病機轉,華杏,第二版,pp.578-83,1995。
146. 洪漢陽及李楫航著,早產兒呼吸暫停,臨床新生兒,嘉洲,第三版,pp157-166,1999。
147. 鄒國英及曹伯年,台灣地區極低出生體重兒之罹病及短期預後,台灣地區早產兒之罹病與死亡情形,中華民國新生兒科醫學會,pp. 1-16,2001

------------------------------------------------------------------------ 第 2 筆 ---------------------------------------------------------------------
系統識別號 U0026-0812200915154242
論文名稱(中文) 微機電感應器應用於睡眠呼吸暫停障礙評估系統設計
論文名稱(英文) Application of MEMS Type Sensors in Designing an Evaluation System for Obstructive Sleep Apnea
校院名稱 成功大學
系所名稱(中) 電機工程學系專班
系所名稱(英) Department of Electrical Engineering (on the job class)
學年度 97
學期 2
出版年 98
研究生(中文) 蔡勝仁
學號 N2795128
學位類別 碩士
語文別 中文
口試日期 2009-07-03
論文頁數 54頁
口試委員 口試委員-李彥杰
口試委員-廖斌毅
指導教授-楊明興
關鍵字(中) 微機電系統
睡眠呼吸暫停障礙
三軸加速度計
關鍵字(英) 3 axial Accelerometer
Obstructive Sleep Apnea (OSA)
Micro-Electro-Mechanical Systems (MEMS)
學科別分類
中文摘要 睡眠呼吸暫停障礙是一種在睡眠中才會發生的呼吸疾病,美國以及其他西方國家之成人,有很高的盛行率,在台灣地區,睡眠呼吸暫停症狀的研究已經受到重視,多家醫院都成立睡眠中心。
本系統設計主要是憑藉微機電系統三軸加速度計與微機電系統麥克風,收集睡眠體位、胸腹呼吸動作、口鼻呼吸氣流(或鼾聲)數據,經由硬體處理量測到的信號之後,由USB-6009 DAQ卡擷取,顯示與儲存結果到PC,做為在居家環境下長期的人體睡眠監測和記錄,讓醫生研判病患是否要進一步至睡眠實驗室做檢查之參考。
英文摘要 The Obstructive Sleep Apnea (OSA) is one kind of breath disease occurred in sleeping and is very prevalence among adult in America and the other Western countries. A lot of Taiwan hospitals had established sleep center to study obstructive sleep apnea syndrome due to more and more attention on OSA.
The system is designed to capture sleep posture, chest and abdominal breath movement, nasal and oral airflow (or snoring) signals by MEMS 3 axial Accelerometer and Microphone. USB-6009 DAQ card will acquire the processed data and then store and display result in PC. It will be used as a long-term sleeping monitor and record at home, and provide a reference data for doctor to judge whether his patient has to do more examination in sleep lab or not.
論文目次 目 錄
中文摘要 I
英文摘要 II
誌謝 III
目錄 IV
圖目錄 VII
表目錄 X
第一章 緒論 1
1-1前言 1
1-2研究動機與背景 2
1-3文獻回顧 2
第二章 系統設計 11
2-1系統整體架構 11
2-2 硬體系統設計 12
2-2-1完整線路 12
2-2-2主板與DAQ USB-6009的介面 12
2-2-3主板電源 13
2-2-4三軸加速計輸入及訊號放大電路 14
2-2-5預留電路 15
2-2-6麥克風訊號放大電路 16
2-3微機電系統介紹 17
2-3-1 微機電系統發展簡介 17
2-3-2 Freescare MMA7260QR2 三軸加速計介紹 18
2-4資料擷取卡 23
2-5軟體系統設計 23
2-5-1 生理訊號擷取 23
2-5-2 生理訊號擷取 25
第三章 系統測試與校正 27
3-1 三軸加速計IC在轉動時的輸出電壓值驗證 27
3-2 MIC IC在動作時的輸出測試 30
第四章 實驗程序與結果 32
4-1實驗方法與步驟 32
4-1-1 實驗與記錄 32
4-1-2 播放記錄檔案 35
4-2實驗結果 37
4-2-1 鼾聲 37
4-2-2 睡姿 39
第五章 討論 43
5-1 實驗結果討論 43
5-2 系統設計貢獻 43
5-3 系統問題討論 43
第六章 結論與未來展望 45
6-1 結論 45
6-2 未來展望 45
參考文獻 46
附錄A 三軸加速度計大小 50
附錄B MEMS MIC 大小 50
附錄C 電路板Layout(雙層) 51
附錄D 零件接腳資料 52
自述 54
圖 目 錄
圖1-1 阻塞性(上)及中樞性(下)睡眠呼吸中止 4
圖1-2 左圖為正常呼吸道 右圖為OSA患者呼吸道阻塞變窄異常 5
圖1-3 睡眠多項生理檢查圖解 8
圖1-4 三軸加速度計位置及定義 9
圖1-5 加速度計三軸與姿勢關係實驗數據 10
圖2-1 系統整體架構圖 11
圖2-2 主板完整線路 12
圖2-3 主板與DAQ USB-6009的介面 13
圖2-4 主板電源 13
圖2-5 三軸加速計輸入及訊號放大電路 14
圖2-6 預留電路之一 15
圖2-7 預留電路之二 16
圖2-8 麥克風訊號放大電路 16
圖2-9 簡化的三軸加速計IC內部功能方塊圖 19
圖 2-10 簡化的物理移轉模式 19
圖2-11 MEMS麥克風內部的構造 20
圖2-12 MEMS MIC的應用線路 21
圖2-13-1 傳統ECM(FET)應用線路 21
圖2-13-2傳統ECM(IC)應用線路 21
圖2-14傳統ECM Frequency Response Curve 22
圖2-15 MEMS MIC 100Hz ~ 8kHz Frequency Response Curve 22
圖2-16 生理訊號擷取程式流程圖 23
圖2-17 生理訊號擷取軟體Block diagram 24
圖2-18 黑色波形為取樣波 25
圖2-19生理訊號讀取程式流程圖 25
圖2-20 生理訊號讀取程式Block diagram 26
圖 3-1 三軸加速計旋轉至六個面的三軸及DAQ 擷取輸出的電壓變化 27
圖 3-2 X軸輸出電壓變化 Y軸輸出電壓變化 Z軸輸出電壓變化 28
圖 3-3 當三軸加速計Z軸方向平行於地面,IC輸出電壓變化 28
圖 3-4 身體向左側睡(Left position)時三軸輸出,X 軸輸出將近5V 29
圖 3-5 身體仰臥(Supine position)時三軸輸出,Z 軸輸出將近5V 29
圖3-6 身體向右側睡(Right position)時三軸輸出,X軸輸出將近2V 29
圖3-7 身體坐起來(Sitting position)時三軸輸出,Y軸輸出將近5V 29
圖3-8 身體趴睡(Prone position)時三軸輸出,Z軸輸出將近1.8V 30
圖3-9 三軸加速計箭頭方向為該軸最大值 30
圖3-10 MIC 在動作時的輸出測試 31
圖4-1 三軸加速度計安裝於腹部的位置 33
圖4-2 MEMS MIC安裝在醫學用透明氧氣呼吸面罩內 33
圖4-3整套評估系統安裝 34
圖4-4 PC操作面板 35
圖4-5身體左側睡以及同時打鼾波型 36
表 目 錄
附表一 睡眠呼吸中止症的篩檢 48
附表二 艾普沃斯 嗜睡自我量表 Epworth Sleepiness Scale 49
參考文獻 1. http://www.wrongdiagnosis.com/s/sleep_apnea/stats-country.htm
2. National Sleep Foundation, “Summary of Findings 2005”
http://www.sleepfoundation.org
3. http://www.sleepmed.md/page/1896
4. K.P. Pang, D.J. Terris, R. Podolsky, “Severity of obstructive sleep apnea:
Correlation with clinical examination and patient perception”, Otolary Head Neck Surg, vol. 135, pp. 555-560, 2006.
5. H. Hunsaker, R.H. Riffenburgh, “Snoring significance in patients undergoing home sleep studies”, Otolary Head Neck Surg, vol. 134, pp. 756-760, 2006
6. http://www.aasmnet.org/
7. http://www.sci.org.tw/typsn-fa-3_3.html
8. Varady, P.; Bongar, S.; Benyo, Z. Detection of Airway Obstruction and Sleep Apnea by Analyzing the Phase Relation of Respiration Movement Signals. Instrumentation and Measurement, IEEE Transactions on
Volume 52, Issue 1, Feb. 2003 Page(s):2 - 6
Digital Object Identifier 10.1109/TIM.2003.809095
9.陳濘宏醫師 阻塞性睡眠呼吸中止症候群 林口長庚紀念醫院睡眠中心
10. Willard RM, Dreher M. Wake-up call for sleep apnea.
Nursing. 2005; 35(3): 48.
11. Penzel, T.; Kemp, B.; Klosch, G.; Schlogl, A.; Hasan, J.; Varri, A.;
Korhonen, I.; Acquisition of Biomedical Signals Databases
Engineering in Medicine and Biology Magazine, IEEE Volume 20,
Issue 3, May-June 2001 Page(s):25 - 32
12. Smithson, A.J.; Griffiths, C.J.; Drinnan, M.J.; Gibson, G.J.;
Methods for assessing snoring, Sleep Monitoring, IEE Colloquium on
14 Nov 1995 Page(s):5/1 - 5/3
13. Rendon, D.B.; Ojeda, J.L.R.; Foix, L.F.C.; Morillo, D.S.; Fernandez,
M.A.;
Mapping the Human Body for Vibrations using an Accelerometer
Engineering in Medicine and Biology Society, 2007. EMBS 2007. 29th
Annual International Conference of the IEEE
22-26 Aug. 2007 Page(s):1671 - 1674
14. Yoshifumi Kishimoto, Akimitsu Akahori and Koji Oguri
Estimation of sleeping posture for M-Health by a wearable tri-axis
accelerometer.
International Summer School and Symposium on Medical Devices and Biosensors MIT, Boston, USA, Sept.4-6, 2006
15. http://www.freescale.com/files/sensors/doc/data_sheet/MMA7260QT.pdf?pspll=1
16. C.V.C. Bouten, K.T.M. Koekkoek, M. Verduin, R. Kodde,
J.D. Janssen, “A Triaxial Accelerometer and Portable Data
Processing Unit for the Assessment of Daily Physical Activity,”
in IEEE Trans Biomed Eng, 1997, pp. 136-147.
17. NI USB 6009 DAQ user guide and specifications
http://www.ni.com/pdf/manuals/371303e.pdf
18. 譯者李宛蓉 哈佛醫生的優質睡眠全書 商周出版2007年8月初版
19. Knowles Acoustics SPM0208HE5-SB data sheet

------------------------------------------------------------------------ 第 3 筆 ---------------------------------------------------------------------
系統識別號 U0026-1607201220103000
論文名稱(中文) 阻塞性睡眠呼吸中止症之口腔裝置研發
論文名稱(英文) Development of Oral Appliance for Obstructive Sleep Apnea
校院名稱 成功大學
系所名稱(中) 工程科學系碩博士班
系所名稱(英) Department of Engineering Science
學年度 100
學期 2
出版年 101
研究生(中文) 賴昱斌
學號 N96991445
學位類別 碩士
語文別 中文
口試日期 2012-06-26
論文頁數 53頁
口試委員 指導教授-李輝煌
口試委員-黃聖杰
口試委員-黃登淵
關鍵字(中) 打鼾
睡眠呼吸中止症
有限元素分析
持續性正壓呼吸器
口腔治療裝置
呼吸暫停低通氣指數
關鍵字(英) Snoring
Obstructive Sleep Apnea
Finite Element Analysis
Continuous Positive Air Pressure
Oral appliance
學科別分類
中文摘要 隨著醫療技術的發展,打鼾逐漸被人們重視。打鼾常常被人們誤認為是身體太疲累而造成的生理現象,但打鼾其實是睡眠呼吸中止症症狀之一。睡眠呼吸中止症對人們造成的影響有白天嗜睡、精神不集中、高血壓、心血管疾病甚至發生交通事故,這些看起來不是很明顯,但有時後卻是致命的。
睡眠呼吸中止症的治療方式有利用持續性正壓呼吸器、口腔裝置以及手術治療,而本論文著重在口腔裝置上。口腔裝置現在市面上的產品有超過20種,而大部分在設計上不符合人體工學,所以大部分產品使用起來常常使人們感到不適。
本論文為了改良市面上產品讓使用者感到更符合人體工學並改善呼吸中止症,進而設計一種高靈活度的口腔裝置,本論文設計的裝置主要是利用將下巴往前移動再藉著摩擦力的效果使下巴不會往回收,希望藉此來達到降低打鼾強度及呼吸暫停低通氣指數 (Apnea-hypopnea Index, AHI) 並利用有限元素軟體去分析設計的口腔治療裝置機構上的摩擦力作用是否足夠防止在睡覺時下巴往回收。
從結果可以確定摩擦力的作用是足夠阻止下巴往回收,但是不適用在有磨牙症症狀的病患。
英文摘要 With the development of medical technology, snoring gradually has been attended in recent years. Snoring is usually mistaken for the physiological phenomenon because the body is too tired. Actually, snoring is one of symptoms in obstructive sleep apnea. The obstructive sleep apnea will result in persisting sleepiness in daytime, a lack of concentration, hypertensive crisis, cardiovascular disease and even traffic accidents. These symptoms seem to be unimportant in daily time, but sometimes that are fatal in life.
Present treatments for obstructive sleep apnea include continuous positive air pressure, oral appliances and performing surgery. This thesis focuses on oral appliances. There are more than 20 kinds of oral appliances on the market, but most of them are often not flexible enough to be adjusted to fit these devices to all possible cases. These oral appliances are not ergonomically designed, so patients often feel uncomfortable in using existing produtions.
In order to make users feel more comfortable and improve obstructive sleep apnea effectively, a highly flexible oral appliance has been presented in the study. The oral device uses friction effect to maintain mandibular forward, and ensures that mandibular would not slide back during sleeping. As a result, the conceptual design is developed for reducing intensity of snoring and apnea-hypopnea index. For verifying the appliance is strong enough to prevent mandibular from sliding back, the study uses commonly commercial finite element software ANSYS for analysis.
The results show that friction effect could certainly prevent mandibular from sliding back, but that is not sustainable for those patients with bruxism symptoms. However, patients with bruxism symptoms is adapted for neither oral appliance proposed by this thesis nor others on the market.
論文目次 摘要 I
ABSTRACT II
表目錄 VII
圖目錄 VIII
第一章 緒論 1
1-1前言 1
1-2動機 1
1-3論文架構 2
第二章 研究背景及文獻回顧 4
2-1研究背景 4
2-1-1睡眠週期 4
2-1-2上呼吸道之解剖學 5
2-1-3睡眠呼吸中止症 6
2-1-4 OSA的評估 8
2-1-5 OSA的治療方法 10
2-2文獻回顧 14
第三章 口腔裝置及專利探討 17
3-1口腔裝置 17
3-2專利回顧 18
第四章 口腔裝置設計及有限元素分析 27
4-1口腔裝置設計 27
4-2有限元素分析 32
4-2-1材料設定 32
4-2-2幾何模型 33
4-3邊界條件及分析設定 35
4-4模擬結果 40
第五章 結論與未來展望 43
5-1結論 43
5-2未來展望 44
參考文獻 46
索引 51
參考文獻 [1] Roffwarg et al., “Ontogenetic development of the human sleep-dream cycle,” Science, Vol 152, 604-619, 1966.
[2] Des Jardins, Terry R., Cardiopulmonary Anatomy & Physiology: Essentials for Respiratory Care, 4th ed., Albany Delmar Thomson Learning, Australia, 2002.
[3] 李佩玲醫師,“睡眠呼吸障礙,"台大醫院睡眠中心。
[4] 陳濘宏,“呼吸中止症可從打鼾聲判別?,"商業週刊,第1280期,98-100頁,2012年6月。
[5] Fujita S., “Midline laser glossectomy with linguoplasty: a treatment of sleep apnea syndrome,” Operative Techniques Otolaryngol Head Neck Surg, 2, pp.127-131, 1991.
[6] 蕭光明,“睡眠呼吸中止症外科療法可以完全根治嗎?,”健康世界,新版314期,56-61頁,2012年2月。
[7] Winfried J. Randerath, Markus Heise, Rolf Hinz and Karl-Heinz Ruehle, “An Individually Adjustable Oral Appliance vs Continuous Positive Airway Pressure in Mild-to-Moderate Obstructive Sleep Apnea Syndrome,” CHEST, pp. 569-575, 2002.
[8] Atul Mehta, Jin Qian, Peter Petocz, M. Ali Darendeliler and Peter A. Cistulli, "A Randomized, Controlled Study of a Mandibular Advancement Splint for Obstructive Sleep Apnea," AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 163, 2001.
[9] A. J. Campbell, G. Reynolds, H. Trengrove and A. M. Neill, "Mandibular advancement splint titration in obstructive sleep apnoea," Sleep Breath, vol. 13, pp. 157-162, 2009.
[10] Alister Neill, Robin Whyman, Scott Bannan, Oliver Jeffrey and Angela Campbell, "Mandibular advancement splint improves indices of obstructive sleep apnoea and snoring but side effects are common," Journal of the New Zealand Medical Association, vol. 115, no. 1156, 21 June 2002.
[11] A.D. McGown, H.K. Makker, J.M. Battagel, P.R. LEstrange, H.R. Grant and S.G. Spiro, "Long-term use of mandibular advancement splints for snoring and obstructive sleep apnoea: a questionnaire survey," Eur Respir J, vol. 17, pp. 462-466, 2001.
[12] Ghizlane Aarab, Frank Lobbezoo, Hans L. Hamburger and Machiel Naeije, "Effects of an oral appliance with different mandibular protrusion positions at a constant vertical dimension on obstructive sleep apnea," Clin Oral Invest, no. 14, pp. 339-345, 2010.
[13] Marie-Louise Walker-Engström, Ivar Ringqvist, Olle Vestling, Bo Wilhelmsson, and Åke Tegelberg, "A Prospective Randomized Study Comparing Two Different Degrees of Mandibular Advancement with a Dental Appliance in Treatment of Severe Obstructive Sleep Apnea," vol. 7, no. 3, 2003.
[14] Maree Barnes, R. Douglas McEvoy, Siobhan Banks, Natalie Tarquinio, Christopher G. Murray, Norman Vowles and Robert J. Pierce, " Efficacy of Positive Airway Pressure and Oral Appliance in Mild to Moderate Obstructive Sleep Apnea," AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 170, 2004.
[15] Bondemark L, Lindman R. “Craniomandibular status and function in patients with habitual snoring and obstructive sleep apnea after nocturnal treatment with a mandibular advancement splint: a 2-year follow-up,” Eur J Orthod no. 22, pp.53–60, 2000.
[16] S. Y. Y. Woo, "Articulating connector for mandibular repositioning oral appliance". U.S. Patent 6,012,920, 22 Apr. 1999.
[17] R. S. Callender, "Apparatus for treatment of sleep apnea". U.S. Patent US 2009/0032030 A1, 18 Jan. 2008.
[18] B. D. Fuselier, "Intra-oral apnea and snoring preventiong appliance". U.S. Patent US 2010/0154802 A1, 24 Dec. 2008.
[19] D. C. B. Richard A. Bonato, "Adjustable dental apparatus for reducing snoring and improving sleep disordered breathing". U.S. Patent U.S Patent No. US 2008/0060659 A1, 13 Sep. 2006.
[20] T. E. Meade, "Apparatus and method for the reduction of snoring". U.S. Patent 5,467,783, 6 Dec. 1994.
[21] G. L. L. B. R. D. P. C. S. R. B. K. Eugene N. Scarberry, "Oral appliance for treatment of snoring and sleep apnea". U.S. Patent US 2007/0292819 A1, 11 May 2007.
[22] A. Heine, "Mandibular advancement mouthpiece, an intraoccusal removable improved device for eliminating or reducing snoring". U.S. Patent 2008/0115791 A1, 15 Nov. 2007.
[23] G. Magnin, "Mandibular advancement splint". U.S. Patent US 7,810,503 B2, 11 Jul. 2008.
[24] M. D. F. Don E. Frantz, "Elastic mandibular advancement appliance with slide-in bite planes". U.S. Patent U.S Patent No. 5,947,724, 5 May 1997.
[25] M. D. F. Don E. Frantz, "Elastic mandibular advancement appliance". U.S. Patent 6,109,265, 29 Oct. 1997.
[26] T. E. Meade, "Mandibular advancement appliance". U.S. Patent US 2010/0307511 A1, 9 Dec. 2010.
[27] L. W. Halstrom, "Adjustable dental appliance for treatment of snoring and obstructive sleep apnea". U.S. Patent 5,365,945, 13 Apr. 1993.
[28] E. Sarkisian, "Apparatus and method for caring for obstructive sleep disorder breathing". U.S. Patent 2006/0174897 A1, 10 Aug.2006.
[29] D. F. Fenton, "Anti-snoring device with adjustable upper and lower relational members". U.S. Patent 5,499,633, 19 Mar. 1996.
[30] R. G. Paimisano, "Mandibular advancement device". U.S. Patent 2005/0028826 A1, 11 Aug. 2004.
[31] J. H. T. Mark Van Dyke, “Mandibular advancement splint”. U.S. Patent: 2011/0220125 A1, 15 Mar. 2011.
[32] Scott A. Huge, Arlen J. Hurt, G. Dischinger, “Herbst orthodontic appliance with improved pivot.” U.S. Patent 6.
[33] H. H. Lee, Finite Element Simulations with ANSYS Workbench 12, GOTOP Information Inc., May. 2010.
[34] Carl E. Misch, Comtemporary Implant Dentistry, Mosby Elsevier, 2008
[35] K. NISHIGAWA, E. BANDO and M. NAKANO “Quantitative study of bite force during sleep associated bruxism,” Journal of Oral Rehabilitation, vol. 28, pp.485-491, 2001.

 


如您有疑問,請聯絡圖書館
聯絡電話:(06)2757575#65773
聯絡E-mail:etds@email.ncku.edu.tw